Assembly of linear nano-chains from iron oxide nanospheres with asymmetric surface chemistry.
Besides the multifunctionality, another equally important aspect of nanoparticles is their engineerability to control the geometrical and chemical properties during fabrication. In this work, we exploited this aspect to define asymmetric surface chemistry of an iron oxide nanosphere by controlling the topology of ligand expression on its surface resulting in a particle with two faces, one displaying only amines and the other only thiols. Specifically, amine-functionalized iron oxide nanospheres were attached on a solid support via a crosslinker containing a disulfide bridge. Liberation of the nanosphere using thiolytic cleavage created thiols on the portion of the particle's surface that interacted with the solid support. Employing a solid-phase strategy and a step-by-step addition of particles, the two unique faces on the same nanosphere served as fittings to assemble them into linear nano-chains. Assembly of chains with various lengths and aspect ratios was controlled by the size and number of the added nanospheres. The characteristics of those chains showed a high degree of uniformity indicating the exceptional control of the synthetic process. Notably, one of the unique properties of the iron oxide nano-chains was an increased magnetic relaxivity, indicating their potential use as contrast agents for magnetic resonance imaging.
Department of Biomedical Engineering and Department of Radiology, Case Center for Imaging Research, Case Western Reserve University, Cleveland, Ohio, United States of America.
Pubudu M
PM
Peiris
Erik
E
Schmidt
Michael
M
Calabrese
Efstathios
E
Karathanasis
D000588:Amines; D055598:Chemical Phenomena; D003287:Contrast Media / Q000737:chemistry; D005290:Ferric Compounds / Q000737:chemistry*; D008024:Ligands; D008280:Magnetics; D054118:Nanospheres / Q000737:chemistry*; D013438:Sulfhydryl Compounds; D013499:Surface Properties
D000588:Amines; D003287:Contrast Media; D005290:Ferric Compounds; D008024:Ligands; D013438:Sulfhydryl Compounds; C000499:ferric oxide
Biomaterials. 2008 Jan;29(3):377-84
17936897
Eur J Biochem. 1985 Aug 15;151(1):83-7
2411553
J Am Chem Soc. 2006 Feb 15;128(6):2115-20
16464114
Chem Commun (Camb). 2004 Mar 7;(5):518-9
14973586
Nano Lett. 2008 Feb;8(2):731-6
18269261
Clin Cancer Res. 2009 Jul 15;15(14):4722-32
19584158
Nature. 1996 Apr 11;380(6574):561-2
8606781
Langmuir. 2010 Mar 16;26(6):4281-7
19842632
Lancet Oncol. 2006 Aug;7(8):657-67
16887483
Pharm Res. 2009 Jan;26(1):235-43
18712584
Biochemistry. 1982 Aug 17;21(17):3950-5
7126526
Science. 2005 Nov 18;310(5751):1132-4
16293748
Biomaterials. 2009 May;30(15):2919-28
19230966
Contrast Media Mol Imaging. 2010 Nov-Dec;5(6):318-22
21190269
J Am Chem Soc. 2007 Jan 10;129(1):12-3
17199264
Ann Biomed Eng. 2008 Feb;36(2):254-61
18172768
J Biomed Mater Res A. 2009 Sep 15;90(4):947-58
18646200
Small. 2006 Oct;2(10):1126-9
17193575
Langmuir. 2009 Jul 21;25(14):7910-7
19419188
J Clin Oncol. 2005 Nov 1;23(31):7794-803
16172456
J Am Chem Soc. 2004 Apr 28;126(16):5064-5
15099078
Science. 2006 Oct 27;314(5799):626-30
17068256
Adv Mater. 2008 May 5;20(9):1630-1635
21687830
Science. 2001 Jul 20;293(5529):465-8
11463908
Biomaterials. 2006 Oct;27(30):5307-14
16797691
J Am Chem Soc. 2007 May 2;129(17):5356-7
17425320
Small. 2009 Mar;5(6):694-700
19263431
Small. 2009 Feb;5(2):235-43
19089838
J Control Release. 2005 May 5;104(1):113-28
15866339
Nat Rev Cancer. 2005 Mar;5(3):161-71
15738981
J Am Chem Soc. 2005 Jun 8;127(22):8008-9
15926813
Ann Biomed Eng. 2006 Apr;34(4):633-41
16568349
Science. 1995 Mar 3;267(5202):1275-6
7871422